IMMP News and Press, Immutep Limited From 05/05/25

2025-05-05 11:31:09 ET Immutep Limited (NASDAQ: IMMP) is one of today’s top gainers. The company’s shares have moved 34.21% on the day to $2.29. Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The ...

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1 Mature overall survival data builds on encouraging high response rates with multiple complete responses Patients with CPS <1 rep...

Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestone Pivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2025 Patient enrolment completed for the EFTISARC-NEO Phase II trial evaluating eft...

2025-03-31 11:50:46 ET Summary Immutep's lead program, Eftilagimod Alpha, shows promising data in 1st line with NSCLC and HNSCC trials. Despite positive trial results, IMMP's financials do not reflect its breadth of clinical programs. The company has multiple ongoing programs,...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for Immutep Global Phase III with efti will enrol approximately 756 patients at more than 150 clinical sites Trial results will inform potential marketing approval application in n...

SYDNEY, AUSTRALIA, March 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the piv...

Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approval Mature data from INSIGHT-003 in 1L NSCLC demonstrates an excellent 32.9...

2025-01-28 16:37:29 ET Summary Immutep Limited remains a “Buy” due to promising pipeline updates and strong financials, despite inherent high-risk/high-reward dynamics. Key trials for eftilagimod show encouraging results, particularly in non-small cell lung cancer an...

Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sarcoma reaches enrolment target of 40 patients Data updates from EFTISARC-NEO expected in 2025 SYDNEY, AUSTRALIA, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ...

Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches enrolment target of approximately 50 evaluable patients Data updates from INSIGHT-003 are expected in 2025 and beyond SYDNEY, AUSTRALIA, Jan. 06, 202...